RSS

OSE Immunotherapeutics

Biotechnology company, OSE Immunotherapeutics, has received a grant through the Eurostars European Programme, led by Bpifrance, aimed at the development of rapidly marketable innovative products, processes and services. more

News

The Independent Data Monitoring Committee (IDMC) has approved the continuation of the Phase III clinical study into OSE Immunotherapeutics’ treatment for Non-Small Cell Lung Cancer (NSCLC) — Tedopi — after immune checkpoint inhibitor treatment. more

News